Clinical Trials · NCT07559500
Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Enrollment
- 176
- Start date
- May 2026
- Locations
- 1 site, United States
- Primary endpoint
- Part 1 (n=5 healthy volunteers): We will assess the reproducibility of striatal dopamine (DA) measures in response to iv methylphenidate (MP) using PET/MR combined scanning and the bolus infusion protocol in healthy controls.